Amae Health Secures $25M: Redefining Severe Mental Illness Treatment
November 8, 2025, 3:47 pm
Location: United States, California, Los Angeles
Employees: 10001+
Founded date: 1902
Amae Health secures $25 million in Series B funding, elevating total investment past $50 million. This capital fuels aggressive national clinic expansion and advances Amae's cutting-edge AI-powered precision care platform. The company tackles severe mental illnesses like schizophrenia, bipolar disorder, and treatment-resistant depression. Their integrated in-person and technology-driven model delivers dramatically improved patient outcomes, significantly cutting hospital readmission rates. Amae aims for long-term remission, collaborating with leading health systems and launching a research institute to redefine SMI treatment and pursue a cure.
Amae Health just announced a major financial milestone. The company secured $25 million in Series B financing. This round elevates Amae's total funding past $50 million. Altos Ventures led the investment. Existing investors also participated. Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital, and 8VC all reaffirmed their commitment. This new capital signals strong confidence in Amae's mission.
The investment fuels a clear strategic path. Amae plans significant national expansion. New clinics will open across the country. The funds also advance Amae's proprietary AI-driven care platform. Partnerships with academic medical centers will strengthen. Research into severe mental illness (SMI) will receive further support. Amae Health focuses on conditions devastating families. These include schizophrenia, bipolar disorder, and treatment-resistant depression.
Traditional mental illness treatment often falls short. Millions of Americans live with SMI. Their needs remain largely unmet. Amae Health offers a different approach. It combines compassionate, in-person care with advanced technology. This integrated model is designed for long-term remission. The goal is a true cure. Amae operates as a Public Benefit Corporation. Its commitment to patient outcomes is paramount.
Amae's care model is comprehensive. It features integrated in-person treatment. Multidisciplinary teams staff each clinic. These teams provide psychiatric, therapeutic, and primary care. Nutritional and social services are also included. This holistic approach addresses patient needs entirely. It moves beyond medication alone.
The company opened its first clinic in Los Angeles in 2022. Rapid expansion followed. Amae has since partnered with major health systems. NewYork-Presbyterian, Cedars-Sinai, and Stanford Health Care are key collaborators. These partnerships expand access to Amae's innovative care. They bring specialized SMI treatment to more communities.
Amae's clinical outcomes are exceptional. They set a new benchmark in SMI care. The 30-day hospital readmission rate is less than 4 percent. This significantly beats the national average of 23 percent. This data point highlights effective crisis prevention. It shows successful stabilization.
Measurement-based care scores also reveal dramatic improvements. Patients showed a 76 percent improvement in mania symptoms. Psychosis symptoms improved by 61 percent. Suicidality symptoms decreased by 49 percent. These metrics demonstrate profound impact on patient well-being. They reflect a higher quality of life.
Patient experience remains a top priority. Amae boasts a Net Promoter Score (NPS) of 90. This score reflects outstanding patient satisfaction. It indicates strong patient loyalty. The company also prioritizes timely care. Every patient transitioning from hospitalization receives follow-up care. This happens within seven to thirty days. Amae's same-day intake model makes this possible.
Technology underpins Amae's success. Its AI-powered platform is a game-changer. It leverages Palantir Foundry. This system consolidates vast amounts of patient data. It integrates clinical assessments, wearable device data, and medical histories. Clinicians gain a real-time, comprehensive patient view. This informs precise treatment decisions.
New AI features enhance this platform further. The longitudinal patient dashboard is one such feature. It synthesizes all patient inputs. Providers get a clear, ongoing view of progress. Another feature is the AI-enabled assistant. It monitors patient status. It flags significant changes. It suggests potential treatment pathways. Clinicians retain full control over all decisions.
Symptomology phenotyping is another innovation. This system clusters symptoms from patient data. It creates digital phenotypes. This allows highly individualized care strategies. Treatment adapts to each patient's unique symptom profile. This is true precision medicine in action.
The new funding will accelerate Amae's growth. National expansion is a primary objective. More clinics mean broader reach. Advancing the AI platform remains crucial. Continuous innovation improves patient care. Supporting research into SMI conditions pushes the boundaries of knowledge.
Amae has also established the Amae Institute. This dedicated center focuses on advancing SMI care. It partners with leading research hospitals. Academic experts contribute their knowledge. The Institute aims to develop next-generation treatments. Its ultimate goal is long-term remission and a definitive cure. This commitment extends beyond current clinical practice. It invests in the future of mental health.
Amae Health’s integrated model challenges traditional paradigms. It combines human compassion with technological prowess. It delivers measurable, superior outcomes. The focus on severe mental illness is critical. This underserved population urgently needs new solutions. Amae provides a blueprint for effective, patient-centered care. The company stands as a leader in mental health innovation. Its progress offers hope. It defines a path forward for complex conditions.
Amae Health just announced a major financial milestone. The company secured $25 million in Series B financing. This round elevates Amae's total funding past $50 million. Altos Ventures led the investment. Existing investors also participated. Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital, and 8VC all reaffirmed their commitment. This new capital signals strong confidence in Amae's mission.
The investment fuels a clear strategic path. Amae plans significant national expansion. New clinics will open across the country. The funds also advance Amae's proprietary AI-driven care platform. Partnerships with academic medical centers will strengthen. Research into severe mental illness (SMI) will receive further support. Amae Health focuses on conditions devastating families. These include schizophrenia, bipolar disorder, and treatment-resistant depression.
Traditional mental illness treatment often falls short. Millions of Americans live with SMI. Their needs remain largely unmet. Amae Health offers a different approach. It combines compassionate, in-person care with advanced technology. This integrated model is designed for long-term remission. The goal is a true cure. Amae operates as a Public Benefit Corporation. Its commitment to patient outcomes is paramount.
Amae's care model is comprehensive. It features integrated in-person treatment. Multidisciplinary teams staff each clinic. These teams provide psychiatric, therapeutic, and primary care. Nutritional and social services are also included. This holistic approach addresses patient needs entirely. It moves beyond medication alone.
The company opened its first clinic in Los Angeles in 2022. Rapid expansion followed. Amae has since partnered with major health systems. NewYork-Presbyterian, Cedars-Sinai, and Stanford Health Care are key collaborators. These partnerships expand access to Amae's innovative care. They bring specialized SMI treatment to more communities.
Amae's clinical outcomes are exceptional. They set a new benchmark in SMI care. The 30-day hospital readmission rate is less than 4 percent. This significantly beats the national average of 23 percent. This data point highlights effective crisis prevention. It shows successful stabilization.
Measurement-based care scores also reveal dramatic improvements. Patients showed a 76 percent improvement in mania symptoms. Psychosis symptoms improved by 61 percent. Suicidality symptoms decreased by 49 percent. These metrics demonstrate profound impact on patient well-being. They reflect a higher quality of life.
Patient experience remains a top priority. Amae boasts a Net Promoter Score (NPS) of 90. This score reflects outstanding patient satisfaction. It indicates strong patient loyalty. The company also prioritizes timely care. Every patient transitioning from hospitalization receives follow-up care. This happens within seven to thirty days. Amae's same-day intake model makes this possible.
Technology underpins Amae's success. Its AI-powered platform is a game-changer. It leverages Palantir Foundry. This system consolidates vast amounts of patient data. It integrates clinical assessments, wearable device data, and medical histories. Clinicians gain a real-time, comprehensive patient view. This informs precise treatment decisions.
New AI features enhance this platform further. The longitudinal patient dashboard is one such feature. It synthesizes all patient inputs. Providers get a clear, ongoing view of progress. Another feature is the AI-enabled assistant. It monitors patient status. It flags significant changes. It suggests potential treatment pathways. Clinicians retain full control over all decisions.
Symptomology phenotyping is another innovation. This system clusters symptoms from patient data. It creates digital phenotypes. This allows highly individualized care strategies. Treatment adapts to each patient's unique symptom profile. This is true precision medicine in action.
The new funding will accelerate Amae's growth. National expansion is a primary objective. More clinics mean broader reach. Advancing the AI platform remains crucial. Continuous innovation improves patient care. Supporting research into SMI conditions pushes the boundaries of knowledge.
Amae has also established the Amae Institute. This dedicated center focuses on advancing SMI care. It partners with leading research hospitals. Academic experts contribute their knowledge. The Institute aims to develop next-generation treatments. Its ultimate goal is long-term remission and a definitive cure. This commitment extends beyond current clinical practice. It invests in the future of mental health.
Amae Health’s integrated model challenges traditional paradigms. It combines human compassion with technological prowess. It delivers measurable, superior outcomes. The focus on severe mental illness is critical. This underserved population urgently needs new solutions. Amae provides a blueprint for effective, patient-centered care. The company stands as a leader in mental health innovation. Its progress offers hope. It defines a path forward for complex conditions.